Stock Update (NYSE:PFE): Pfizer’s Lyrica shows no relief from post-traumatic nerve pain

[Reuters] – Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. Currently, there is no . . . → Read More: Stock Update (NYSE:PFE): Pfizer’s Lyrica shows no relief from post-traumatic nerve pain Similar Articles: Stock Update: St. Jude Medical Inc (NYSE:STJ) – St. Jude Medical Announces FDA Approval for Industry’s Only MR-Conditional 5-Column Paddle Lead for the Management of Chronic Pain Market Update (NYSE:BSX): New Data Demonstrate Greater Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System Market Update: St. Jude Medical Inc (NYSE:STJ) – St. Jude Medical’s Axium System Found to Provide Superior Pain Relief Over Traditional Spinal Cord Stimulation for the Treatment of Chronic Lower Limb Pain
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.